Text Size

Spermatogonial Stem Cells in Azoospermic Patients: a Comparison Between Obstructive and Non-obstructive Azoospermia

The recruitment status of this study is unknown because the information has not been verified recently.
Verified August 2010 by Hillel Yaffe Medical Center.
Recruitment status was  Active, not recruiting
Sponsor:
Information provided by:
Hillel Yaffe Medical Center
ClinicalTrials.gov Identifier:
NCT01178463
First received: August 9, 2010
Last updated: NA
Last verified: August 2010
History: No changes posted
  Purpose

The researchers hypothesized that nonobstructive azoospermia might be associated with a reduction OF SSCs in seminiferous tubules as compared with obstructive azoospermia. Testicular sperm specimens that had been previously extracted from azoospermic patients will be paraffin embedded and stained with anti GPR-125. After antigen retrieval, the sections will be incubated with rabbit anti GPR125 followed by Cy3-conjugated anti rabbit secondary antibodies. Those found to be SSCs will be counted using light microscopy, and compared between patients with obstructive (n=11) and non-obstructive azoospermia (n=9).


Condition Intervention
Male Infertility
 Other: Biospecimen staining

Study Type: Observational
Study Design: Observational Model: Cohort
Time Perspective: Retrospective

Resource links provided by NLM:

U.S. FDA Resources

Further study details as provided by Hillel Yaffe Medical Center:

Primary Outcome Measures:
  • SSCs were identified in both obstructive and nonobstructive azoospermia patients. [ Time Frame: One year ] [ Designated as safety issue: No ]

Estimated Enrollment: 25
Study Start Date: January 2010
Estimated Study Completion Date: October 2010
Primary Completion Date: May 2010 (Final data collection date for primary outcome measure)
Groups/Cohorts Assigned Interventions
I. Obstructive Azoospermia Other: Biospecimen staining
The sections will be incubated with rabbit anti GPR125 followed by Cy3-conjugated anti rabbit secondary antibodies.
II. Non-Obstructive Azoospermia Patients Other: Biospecimen staining
The sections will be incubated with rabbit anti GPR125 followed by Cy3-conjugated anti rabbit secondary antibodies.

  Eligibility

Ages Eligible for Study:   18 Years and older
Genders Eligible for Study:   Male
Accepts Healthy Volunteers:   No
Sampling Method:   Probability Sample
Study Population

Infertile male patients treated at the Hillel Yaffe Medical Center IVF Unit

Criteria

Inclusion Criteria:

  • Azoospermic patients

Exclusion Criteria:

  • Patients with sperm cells
  Contacts and Locations
Please refer to this study by its ClinicalTrials.gov identifier: NCT01178463

Locations
Israel
Hillel Yaffe Medical Center - IVF Unit
Hadera, Israel, 38100
Sponsors and Collaborators
Hillel Yaffe Medical Center
  More Information

No publications provided

Responsible Party: Dr. Adrian Ellenbogen, Hillel Yaffe Medical Center
ClinicalTrials.gov Identifier: NCT01178463     History of Changes
Other Study ID Numbers: HYMC-0065-09
Study First Received: August 9, 2010
Last Updated: August 9, 2010
Health Authority: Israel: Ministry of Health

Additional relevant MeSH terms:
Infertility
Infertility, Male
Genital Diseases, Male
Genital Diseases, Female

ClinicalTrials.gov processed this record on May 19, 2013